In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Raushan T. Kurmasheva; Stephen W. Erickson; Ruolan Han; Beverly A. Teicher; Malcolm A. Smith; Michael Roth; Richard Gorlick; Peter J. Houghton

doi:10.1002/pbc.29304

In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Raushan T. Kurmasheva, Stephen W. Erickson, Ruolan Han, Beverly A. Teicher, Malcolm A. Smith, Michael Roth, Richard Gorlick, Peter J. Houghton

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP-2577 (100 mg/kg/day × 28 days) statistically significantly (p <.05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts. The increase in EFS T/C was modest (<1.5) for all models except RMS Rh10 (EFS T/C = 2.8). There were no tumor regressions or consistent changes in dimethyl histone H3(K4), HOXM1, DAX1, c-MYC and N-MYC, or tumor histology/differentiation. SP-2577 has limited activity against these pediatric sarcoma models at the dose and schedule evaluated.

Original language	English (US)
Article number	e29304
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	11
DOIs	https://doi.org/10.1002/pbc.29304
State	Published - Nov 2021

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.29304

Fingerprint

Dive into the research topics of 'In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)'. Together they form a unique fingerprint.

Cite this

Kurmasheva, R. T., Erickson, S. W., Han, R., Teicher, B. A., Smith, M. A., Roth, M., Gorlick, R., & Houghton, P. J. (2021). In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). Pediatric Blood and Cancer, 68(11), Article e29304. https://doi.org/10.1002/pbc.29304

In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). / Kurmasheva, Raushan T.; Erickson, Stephen W.; Han, Ruolan et al.
In: Pediatric Blood and Cancer, Vol. 68, No. 11, e29304, 11.2021.

Research output: Contribution to journal › Article › peer-review

Kurmasheva, RT, Erickson, SW, Han, R, Teicher, BA, Smith, MA, Roth, M, Gorlick, R & Houghton, PJ 2021, 'In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)', Pediatric Blood and Cancer, vol. 68, no. 11, e29304. https://doi.org/10.1002/pbc.29304

@article{850709b575dd4679940b6498a0dc7a14,

title = "In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)",

abstract = "SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP-2577 (100 mg/kg/day × 28 days) statistically significantly (p <.05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts. The increase in EFS T/C was modest (<1.5) for all models except RMS Rh10 (EFS T/C = 2.8). There were no tumor regressions or consistent changes in dimethyl histone H3(K4), HOXM1, DAX1, c-MYC and N-MYC, or tumor histology/differentiation. SP-2577 has limited activity against these pediatric sarcoma models at the dose and schedule evaluated.",

author = "Kurmasheva, {Raushan T.} and Erickson, {Stephen W.} and Ruolan Han and Teicher, {Beverly A.} and Smith, {Malcolm A.} and Michael Roth and Richard Gorlick and Houghton, {Peter J.}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2021",

month = nov,

doi = "10.1002/pbc.29304",

language = "English (US)",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models

T2 - A report from the Pediatric Preclinical Testing Consortium (PPTC)

AU - Kurmasheva, Raushan T.

AU - Erickson, Stephen W.

AU - Han, Ruolan

AU - Teicher, Beverly A.

AU - Smith, Malcolm A.

AU - Roth, Michael

AU - Gorlick, Richard

AU - Houghton, Peter J.

PY - 2021/11

Y1 - 2021/11

N2 - SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP-2577 (100 mg/kg/day × 28 days) statistically significantly (p <.05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts. The increase in EFS T/C was modest (<1.5) for all models except RMS Rh10 (EFS T/C = 2.8). There were no tumor regressions or consistent changes in dimethyl histone H3(K4), HOXM1, DAX1, c-MYC and N-MYC, or tumor histology/differentiation. SP-2577 has limited activity against these pediatric sarcoma models at the dose and schedule evaluated.

AB - SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP-2577 (100 mg/kg/day × 28 days) statistically significantly (p <.05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts. The increase in EFS T/C was modest (<1.5) for all models except RMS Rh10 (EFS T/C = 2.8). There were no tumor regressions or consistent changes in dimethyl histone H3(K4), HOXM1, DAX1, c-MYC and N-MYC, or tumor histology/differentiation. SP-2577 has limited activity against these pediatric sarcoma models at the dose and schedule evaluated.

UR - http://www.scopus.com/inward/record.url?scp=85113625092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113625092&partnerID=8YFLogxK

U2 - 10.1002/pbc.29304

DO - 10.1002/pbc.29304

M3 - Article

C2 - 34453478

AN - SCOPUS:85113625092

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

M1 - e29304

ER -

In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this